| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
Capricor Therapeutics (NASDAQ:CAPR) is set to give its latest quarterly earnings report on Monday, 2025-11-10. Here's what investors need to know before the announcement.
Analysts estimate that Capricor Therapeutics will report an earnings per share (EPS) of $-0.54.
Capricor Therapeutics bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
During the last quarter, the company reported an EPS missed by $0.09, leading to a 2.88% increase in the share price on the subsequent day.
Here's a look at Capricor Therapeutics's past performance and the resulting price change:
| Quarter | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|---|
| EPS Estimate | -0.48 | -0.32 | -0.31 | -0.36 |
| EPS Actual | -0.57 | -0.53 | -0.16 | -0.38 |
| Price Change % | 3.00 | 5.00 | 18.00 | 9.00 |
Shares of Capricor Therapeutics were trading at $6.28 as of November 06. Over the last 52-week period, shares are down 68.73%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release.
To track all earnings releases for Capricor Therapeutics visit their earnings calendar on our site.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
Posted In: CAPR
